Q1 2023 EPS Estimates for Lumos Pharma, Inc. (NASDAQ:LUMO) Decreased by Analyst

Lumos Pharma, Inc. (NASDAQ:LUMOGet Rating) – Equities research analysts at HC Wainwright decreased their Q1 2023 earnings per share (EPS) estimates for shares of Lumos Pharma in a note issued to investors on Thursday, March 2nd. HC Wainwright analyst E. White now expects that the company will earn ($1.15) per share for the quarter, down from their previous forecast of ($0.98). The consensus estimate for Lumos Pharma’s current full-year earnings is ($4.49) per share. HC Wainwright also issued estimates for Lumos Pharma’s Q2 2023 earnings at ($1.25) EPS, Q3 2023 earnings at ($1.32) EPS, Q4 2023 earnings at ($1.37) EPS, FY2023 earnings at ($5.08) EPS, FY2024 earnings at ($4.97) EPS and FY2025 earnings at ($4.86) EPS.

A number of other equities research analysts have also recently issued reports on the company. Oppenheimer reduced their price objective on Lumos Pharma to $18.00 in a report on Thursday, November 17th. Jefferies Financial Group cut shares of Lumos Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, December 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Lumos Pharma in a research report on Tuesday, November 15th.

Lumos Pharma Trading Up 4.2 %

Shares of Lumos Pharma stock opened at $3.49 on Monday. The stock’s fifty day simple moving average is $3.55 and its 200 day simple moving average is $6.04. Lumos Pharma has a 12 month low of $2.95 and a 12 month high of $10.17. The company has a market capitalization of $29.32 million, a PE ratio of -0.94 and a beta of 0.99.

Hedge Funds Weigh In On Lumos Pharma

Several institutional investors have recently bought and sold shares of LUMO. Virtu Financial LLC purchased a new stake in Lumos Pharma in the 4th quarter worth $38,000. Shay Capital LLC acquired a new position in Lumos Pharma in the fourth quarter valued at approximately $180,000. Millennium Management LLC acquired a new stake in shares of Lumos Pharma in the fourth quarter valued at approximately $72,000. Jefferies Financial Group Inc. acquired a new stake in shares of Lumos Pharma during the fourth quarter worth $436,000. Finally, Envestnet Asset Management Inc. purchased a new position in Lumos Pharma in the fourth quarter worth $38,000. Institutional investors own 30.53% of the company’s stock.

Lumos Pharma Company Profile

(Get Rating)

Lumos Pharma, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Further Reading

Earnings History and Estimates for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.